Needham analyst Serge Belanger maintained a Buy rating on Arcutis Biotherapeutics today and set a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger has given his Buy rating due to a combination of factors including Arcutis Biotherapeutics’ strong financial performance in the third quarter of 2025. The company reported total sales of Zoryve at $99.2 million, which not only marked a significant increase both quarter-over-quarter and year-over-year but also exceeded market expectations. This growth was attributed to an increase in prescriptions and improved gross-to-net adjustments.
Additionally, the collaboration with Kowa and recent label expansions are anticipated to sustain this upward trajectory into 2026. Another key factor in the Buy rating is Arcutis Biotherapeutics’ achievement of positive net income for the first time, alongside their initial 2026 sales guidance that surpasses market projections. These elements, combined with plans to broaden Zoryve’s application to new indications, underpin the decision to maintain a Buy rating and adjust the price target to $30.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARQT in relation to earlier this year.